Translational Development Acquisition

Translational Development Acquisition Equity

The The Equity of Translational Development Acquisition (TDAC) as of Nov 14, 2026 is 175.12 M USD. In the previous year, The Equity was 168.75 M USD — a change of 3.77% (higher).

Equity

175.12 MUSD

YoY

3.77%

Last updated:

In 2025, Translational Development Acquisition's equity was 175.12 M USD, a 3.77% increase from the 168.75 M USD equity in the previous year.

The Translational Development Acquisition Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
-22,108.00 USD
Jan 1, 2023
-507,658.00 USD
Jan 1, 2024
168.75 M USD
Jan 1, 2025
175.12 M USD
The Translational Development Acquisition Equity history
YEAREquityYoY
175.12 MUSD+3.77%
168.75 MUSD-33,341.43%
-507,658.00USD+2,196.26%
-22,108.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Translational Development Acquisition Stock analysis

What does Translational Development Acquisition do? Translational Development Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company has not selected any specific business combination target and has not engaged in any substantive discussions with potential targets. It has neither generated revenues nor conducted any operations since its formation. The firm's business model relies on identifying and executing a future business combination to create value for its shareholders. The company's primary revenue source will come from the successful completion of a business combination, which typically involves acquiring a target company or asset. As a blank check company, it does not operate any business or generate income until a merger or acquisition is finalized. The firm's investors, who purchase shares during its IPO, expect the company to identify and acquire a target business that will provide returns on their investment. Translational Development Acquisition Corp is structured as a special purpose acquisition company (SPAC) that has not yet identified a target business. Its success depends entirely on finding and merging with a suitable company within the timeframe specified in its prospectus. The firm's investors are the primary buyers of its shares, anticipating capital appreciation once a business combination is executed. Translational Development Acquisition is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Translational Development Acquisition's Equity

Translational Development Acquisition's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Translational Development Acquisition's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Translational Development Acquisition's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Translational Development Acquisition's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Translational Development Acquisition’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Translational Development Acquisition stock

The Equity of Translational Development Acquisition is 175.12 M USD in 2025.

The Equity of Translational Development Acquisition changed from 168.75 M USD to 175.12 M USD, representing a 3.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Translational Development Acquisition since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Translational Development Acquisition historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Translational Development Acquisition

All Key Metrics — Translational Development Acquisition